| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9327466 | Gynecologic Oncology | 2005 | 6 Pages |
Abstract
Stage I-II (occult) endometrial adenocarcinoma treated with postoperative HDR vaginal brachytherapy has similar overall survival, locoregional failure rates, and cumulative recurrence rates to standard fractionation external beam pelvic RT with the benefit of much lower toxicity rates and shorter overall treatment time.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Shruti Jolly, Carlos Vargas, Tushar Kumar, Sheldon Weiner, Donald Brabbins, Peter Chen, William Floyd, Alvaro A. Martinez,